Previous 10 | Next 10 |
NovoCure (NASDAQ: NVCR ) is scheduled to announce Q3 earnings results on Thursday, October 31st, before market open. The consensus EPS Estimate is -$0.04 (+69.2% Y/Y) and the consensus Revenue Estimate is $87.12M (+34.5% Y/Y). Over the last 1 year, nvcr has beaten EPS estimates 0% of...
Original Post Editor's Note : The summary bullets for this article were chosen by Seeking Read more ...
Novocure (NASDAQ: NVCR) announced today that it will report financial results for the third quarter 2019 on Thursday, October 31, 2019, before the U.S. financial markets open. Novocure management will host a conference call and webcast to discuss its financial results for the three and nine m...
Introduction: Novocure ( NVCR ) is a mid-cap medical devices company which has a growing pipeline of clinical trials to treat cancer patients with its Tumor Treating Fields. Successful clinical trials in Glioblastoma have now led the treatment to be commercially available . The company is c...
The volume of Tumor Treating Fields presentations marks a record number of abstracts for Novocure at one of the premier meetings for radiation oncologists Highlights include a subgroup analysis of the STELLAR trial by radiological response patterns in malignant pleural mesothelioma and...
The following slide deck was published by NovoCure Limited in conjunction with this Read more ...
Medical science has come a long way from the days when plague doctors wore scary, long-beaked masks and prescribed a steady treatment of leeches and stabbing to cure a head cold. These days, leading American healthcare stocks employ state-of-the-art technology to excel at both saving live...
This is a special contribution article by Prof. Grant Henning based on his published research on the BLM technical theory . The model, his trailing stop-loss approach, and comments are expressly based on his own proprietary methodology and forecasts in the references below. Winning Bounc...
Recently, the DOW plunged 800 points—about 3 percent overall—due to fears that a so-called “recession 2019” might be similar to the one experienced in 2008. Exasperating those fears is the fact that the benchmark 10-year Treasury bond yield broke below the two-...
Race car driver Mikaela Ahlin-Kottulinsky and her helmet (photo via Forbes ). Bulletproof Investing: Week 91 Performance Each week, since the beginning of June 2017, I have presented at least two hedged portfolios created by Portfolio Armor to my Bulletproof Investing subscribers. This ...
News, Short Squeeze, Breakout and More Instantly...
2024-07-25 17:30:15 ET Image source: The Motley Fool. NovoCure (NASDAQ: NVCR) Q2 2024 Earnings Call Jul 25, 2024 , 8:00 a.m. ET Operator Continue reading For further details see: NovoCure (NVCR) Q2 2024 Earnings Call Transcript
Quarterly net revenues of $150 million, up 19% year-over-year, with 3,963 active patients on therapy as of June 30, 2024 Positive results from Phase 3 METIS trial in brain metastases from non-small cell lung cancer presented at ASCO 2024 Novocure (NASDAQ: NVCR) today reported fi...
Novocure (NASDAQ: NVCR) announced today that it will report financial results for the second quarter 2024 on Thursday, July 25, 2024, before the U.S. financial markets open. Novocure management will host a conference call and webcast to discuss the company’s financial results for the three...